Literature DB >> 16923027

Prediction of activity, synthesis and biological testing of anti-HSV active peptides.

Håvard Jenssen1, Tore J Gutteberg, Øystein Rekdal, Tore Lejon.   

Abstract

Herpes simplex virus infections can be treated with a number of drugs, but as for all pathogens, there is a constant need for new therapies. In the search for lead compounds some peptides have proven to possess an antiviral effect, but it is still unclear what mechanisms are responsible for this effect. We wish to report on the use of principal properties of amino acids for developing quantitative structure-activity relationships (QSAR:s) as a tool for modelling peptide activity and predicting the activity of new peptides. In order to test the reliability of the method, new peptides have been designed by using multivariate methodology, synthesized and tested for a number of responses. Two of the new peptides synthesized were active at lower concentrations than experienced before regarding entry and herpes simplex virus activity, but they were not able to completely inhibit viral infection. This may reflect differences in mode of action of peptides depending on the amino acid content.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16923027     DOI: 10.1111/j.1747-0285.2006.00412.x

Source DB:  PubMed          Journal:  Chem Biol Drug Des        ISSN: 1747-0277            Impact factor:   2.817


  3 in total

1.  Therapeutic approaches using host defence peptides to tackle herpes virus infections.

Authors:  Håvard Jenssen
Journal:  Viruses       Date:  2009-11-18       Impact factor: 5.048

2.  In Vivo, In Vitro, and In Silico Characterization of Peptoids as Antimicrobial Agents.

Authors:  Ann M Czyzewski; Håvard Jenssen; Christopher D Fjell; Matt Waldbrook; Nathaniel P Chongsiriwatana; Eddie Yuen; Robert E W Hancock; Annelise E Barron
Journal:  PLoS One       Date:  2016-02-05       Impact factor: 3.240

3.  Comparison of Anti-Viral Activity of Frog Skin Anti-Microbial Peptides Temporin-Sha and [K³]SHa to LL-37 and Temporin-Tb against Herpes Simplex Virus Type 1.

Authors:  Maëva Roy; Lucie Lebeau; Céline Chessa; Alexia Damour; Ali Ladram; Bruno Oury; David Boutolleau; Charles Bodet; Nicolas Lévêque
Journal:  Viruses       Date:  2019-01-18       Impact factor: 5.048

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.